The Scottish Institute for Cell Signalling (SCILLS) and the MRC Protein Phosphorylation Unit will be merging into a new MRC Protein Phosphorylation and Ubiquitylation Unit at the end of March 2013.
To mark this important event, but also to celebrate previous achievements of SCILLS and the MRC-PPU that have brought us to where we are now, we are delighted to announce that Tony Pawson , OC OOnt CH FRS FRSC working at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto will deliver an inaugural lecture of our new Unit at 1 pm on Wednesday 27 March 2013 in the MSI Small Lecture Theatre.
Tony Pawson is one of one of the leading players in cell-signalling field. His lab has contributed to many great advances. Tony Pawson was the first recognise that Src homology 2 (SH2) domains functioned to recognise specific phosphorylated tyrosine residues. This led to the discovery that receptor tyrosine kinases operate to create docking sites for the SH2 domains on diverse effectors. This simple mechanism enables tyrosine kinase receptors to link to specific target effectors in response to signals such as growth factors.
In more recent work Tony Pawson's lab has gone on to identify many different modular domains on proteins that control protein-protein or protein-lipid interactions modulated by diverse extracellular signals. This has made an incredibly important contribution to establishing the multi-domain nature and modularity of cell regulatory proteins relevant for understanding the dynamic organisation of normal cells, the evolution and function of multi-cellular animals, and the genesis of disease.
The research undertaken in the Pawson lab has provided a framework of knowledge that has enabled many signalling pathways to be dissected and helped reveal how disruptions in these pathways cause many diseases including cancer, diabetes and immune disorders. These findings have been instrumental in the development of new kinase inhibitor therapies targeting signalling pathway components that are benefiting many cancer patients (soon patients with immune disorders) which currently generate approximately $20 billion dollars of sales annually .
Tony Pawson's contributions have been recognised by many significant prizes including the Gairdner Foundation International Award, Wolf Prize in Medicine, The Royal Medal from The Royal Society of London, a Companion of Honour and more recently the Kyoto Prize - "Japan's Nobel".
To mark this important event, but also to celebrate previous achievements of SCILLS and the MRC-PPU that have brought us to where we are now, we are delighted to announce that Tony Pawson , OC OOnt CH FRS FRSC working at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto will deliver an inaugural lecture of our new Unit at 1 pm on Wednesday 27 March 2013 in the MSI Small Lecture Theatre.
Tony Pawson is one of one of the leading players in cell-signalling field. His lab has contributed to many great advances. Tony Pawson was the first recognise that Src homology 2 (SH2) domains functioned to recognise specific phosphorylated tyrosine residues. This led to the discovery that receptor tyrosine kinases operate to create docking sites for the SH2 domains on diverse effectors. This simple mechanism enables tyrosine kinase receptors to link to specific target effectors in response to signals such as growth factors.
In more recent work Tony Pawson's lab has gone on to identify many different modular domains on proteins that control protein-protein or protein-lipid interactions modulated by diverse extracellular signals. This has made an incredibly important contribution to establishing the multi-domain nature and modularity of cell regulatory proteins relevant for understanding the dynamic organisation of normal cells, the evolution and function of multi-cellular animals, and the genesis of disease.
The research undertaken in the Pawson lab has provided a framework of knowledge that has enabled many signalling pathways to be dissected and helped reveal how disruptions in these pathways cause many diseases including cancer, diabetes and immune disorders. These findings have been instrumental in the development of new kinase inhibitor therapies targeting signalling pathway components that are benefiting many cancer patients (soon patients with immune disorders) which currently generate approximately $20 billion dollars of sales annually .
Tony Pawson's contributions have been recognised by many significant prizes including the Gairdner Foundation International Award, Wolf Prize in Medicine, The Royal Medal from The Royal Society of London, a Companion of Honour and more recently the Kyoto Prize - "Japan's Nobel".